ALX ONCOLOGY HOLDINGS INC - 8-K Filing
ALX Oncology reported Q1 2026 financial results with $169.1M in cash, cash equivalents and investments as of March 31, 2026. R&D expenses were $13.6M for the quarter compared to $23.9M a year ago due to workforce reductions and strategic changes; G&A expenses were $5.4M versus $7.9M in Q1 2025. The company also announced positive data from its Phase 1b/2 trial of evorpacept + zanidatamab, showing durable responses in HER2-positive breast cancer patients with high CD47 expression and appointed Jeff Knight as Chief Development and Operating Officer. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ALXO